Understand the source comparison
Pe-22-28 for Antidepressant Research: Mechanism Comparison
This table compares Pe-22-28's neuroplastic mechanism against three major antidepressant drug classes to clarify how each approach addresses different aspects of depressive pathology. Primary Target BDNF/TrkB signaling, neurotrophin upregulation Serotonin tran
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares Pe-22-28's neuroplastic mechanism against three major antidepressant drug classes to clarify how each approach addresses different aspects of depressive pathology.
- Primary Target
- BDNF/TrkB signaling, neurotrophin upregulation
- Serotonin transporter (SERT) inhibition
- Serotonin and norepinephrine transporter inhibition
- Multiple receptors (SERT, NET, H1, M1)
- Pe-22-28 targets structural repair; others modulate neurotransmitter levels
- Neurogenesis Promotion
- Direct stimulation of hippocampal neural progenitor cells
- Indirect, via sustained serotonergic signaling over 4–8 weeks
- Indirect, similar to SSRIs but with dual pathway
- Minimal neurogenic effect documented
- Only Pe-22-28 acts directly on neurogenesis pathways
- Onset in Preclinical Models
- 7–10 days (behavioral assays)
- 14–21 days (behavioral assays)
- 14–21 days
- 14–28 days
- Pe-22-28 shows faster behavioral effects in rodent models
- Hippocampal BDNF Increase
- ~40% elevation at 14 days (rodent models)
- 15–25% elevation at 28 days (requires sustained use)
- Similar to SSRIs
- Minimal documented effect
- Pe-22-28 produces larger BDNF elevation in shorter timeframe
- Adverse Event Profile
- Minimal documented; intranasal irritation reported
- GI disturbance (30–40%), sexual dysfunction (40–60%), weight gain
- Similar to SSRIs plus elevated BP risk
- Anticholinergic effects, sedation, cardiotoxicity risk
- Pe-22-28 avoids receptor-mediated side effects common to all three classes
- Structural Brain Changes
- Reverses stress-induced hippocampal volume loss (animal models)
- Modest hippocampal volume increase after 6+ months
- No consistent structural changes documented
- Pe-22-28 produces measurable structural restoration in preclinical studies
- Pe-22-28's neurogenic mechanism fills a gap conventional antidepressants don't address directly. While SSRIs and SNRIs eventually trigger downstream BDNF increases, Pe-22-28 stimulates neurotrophin pathways from the first dose—explaining faster onset and more pronounced structural changes in hippocampal imaging studies.